Recombinetics Inc. announced a research collaboration with AstraZeneca in a first of its kind study to inform the knowledge base of Neurofibromatosis Type 1 (NF1). NF1 is a pediatric disease that affects 1 in 3,000 births. NF1 patients suffer from a variety of manifestations including learning disabilities, scoliosis, and are predisposed to tumor development. In April 2020, selumetinib became the first FDA approved therapy for NF1 patients for the treatment of symptomatic, inoperable plexiform neurofibromas.